Estrogens conjugated
Amnestrogen, Duavee, Estratab, Evex, Femogen, Menest, Menrium, Milprem, Pmb, Premarin, Premphase, Prempro (estrogens, conjugated) is an unknown pharmaceutical. Estrogens, conjugated was first approved as Menrium 5-2 on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cenestin | New Drug Application | 2004-09-01 |
| duavee | New Drug Application | 2024-07-15 |
| enjuvia | New Drug Application | 2010-03-01 |
| menest | ANDA | 2024-02-23 |
| premarin | New Drug Application | 2024-08-08 |
| premphase | ANDA | 2012-11-26 |
| premphase prempro | New Drug Application | 2024-02-20 |
| prempro | New Drug Application | 2021-02-05 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
3549 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 270 | 720 | 320 | 50 | 253 | 1502 |
| Infertility | D007246 | HP_0000789 | — | 14 | 27 | 40 | 57 | 79 | 202 |
| Neoplasms | D009369 | — | C80 | 60 | 55 | 17 | 3 | 20 | 137 |
| Carcinoma | D002277 | — | C80.0 | 19 | 66 | 25 | 3 | 19 | 125 |
| Syndrome | D013577 | — | — | 8 | 26 | 25 | 30 | 41 | 125 |
| Menopause | D008593 | EFO_0003922 | N95 | 17 | 22 | 22 | 29 | 34 | 119 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 8 | 12 | 29 | 31 | 43 | 118 |
| Healthy volunteers/patients | — | — | — | 87 | 8 | 5 | 4 | 13 | 112 |
| Triple negative breast neoplasms | D064726 | — | — | 33 | 53 | 8 | 2 | 4 | 87 |
| Postmenopause | D017698 | — | — | 16 | 24 | 20 | 11 | 20 | 85 |
Show 217 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 11 | 45 | 19 | — | 9 | 78 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 8 | 40 | 7 | — | 9 | 57 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 15 | 35 | 9 | — | 3 | 56 |
| Carcinoma in situ | D002278 | — | D09.9 | 4 | 23 | 6 | — | 6 | 38 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 8 | 21 | 9 | — | — | 36 |
| Intraductal carcinoma noninfiltrating | D002285 | — | D05.1 | 3 | 20 | 4 | — | 4 | 30 |
| Ductal carcinoma | D044584 | — | — | 7 | 16 | 3 | — | 1 | 24 |
| Coronary disease | D003327 | — | — | — | 3 | 12 | — | 5 | 18 |
| Lobular carcinoma | D018275 | EFO_0000570 | — | 2 | 9 | 1 | — | 6 | 18 |
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | 5 | 3 | — | 11 | 18 |
Show 109 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 12 | 8 | — | — | 1 | 18 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 9 | 7 | — | — | — | 13 |
| Tissue adhesions | D000267 | — | — | 3 | 1 | — | — | 10 | 13 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | 1 | 10 | — | — | — | 10 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 4 | 4 | — | — | 2 | 9 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 4 | — | — | 4 | 8 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 5 | 1 | — | — | 2 | 8 |
| Inflammation | D007249 | MP_0001845 | — | 2 | 5 | — | — | 3 | 8 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 3 | — | — | 1 | 6 |
| Central nervous system neoplasms | D016543 | — | — | 1 | 6 | — | — | — | 6 |
Show 183 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 11 | — | — | — | 1 | 12 |
| Drug interactions | D004347 | — | — | 4 | — | — | — | 2 | 6 |
| Hepatitis c | D006526 | — | B19.2 | 5 | — | — | — | — | 5 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | 1 | — | — | — | 3 | 4 |
| Headache | D006261 | HP_0002315 | R51 | 1 | — | — | — | 3 | 4 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | 2 | 3 |
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | 1 | — | — | — | 2 | 3 |
| Hyperinsulinism | D006946 | HP_0000842 | E16.1 | 1 | — | — | — | 2 | 3 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 3 | — | — | — | — | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | — | — | 1 | 2 |
Show 45 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menstrual cycle | D008597 | — | — | — | — | — | — | 5 | 5 |
| Eclampsia | D004461 | HP_0100601 | O15 | — | — | — | — | 3 | 3 |
| Blood pressure | D001794 | EFO_0004325 | — | — | — | — | — | 3 | 3 |
| Lichen sclerosus et atrophicus | D018459 | — | L90.0 | — | — | — | — | 3 | 3 |
| Gender identity | D005783 | — | — | — | — | — | — | 3 | 3 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 2 | 2 |
| Pregnancy rate | D018873 | — | — | — | — | — | — | 2 | 2 |
| Feeding behavior | D005247 | — | — | — | — | — | — | 2 | 2 |
| Cerebrospinal fluid leak | D065634 | — | G96.0 | — | — | — | — | 2 | 2 |
| Glucose metabolism disorders | D044882 | — | — | — | — | — | — | 2 | 2 |
Show 137 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Estrogens conjugated |
| INN | — |
| Description | Conjugated estrogens (CEs), or conjugated equine estrogens (CEEs), sold under the brand name Premarin among others, is an estrogen medication which is used in menopausal hormone therapy and for various other indications. It is a mixture of the sodium salts of estrogen conjugates found in horses, such as estrone sulfate and equilin sulfate. CEEs are available in the form of both natural preparations manufactured from the urine of pregnant mares and fully synthetic replications of the natural preparations. They are formulated both alone and in combination with progestins such as medroxyprogesterone acetate. CEEs are usually taken by mouth, but can also be given by application to the skin or vagina as a cream or by injection into a blood vessel or muscle.
|
| Classification | Unknown |
| Drug class | estrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 12126-59-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201649 |
| ChEBI ID | — |
| PubChem CID | 656613 |
| DrugBank | DB00286 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Premarin – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 71,309 documents
View more details
Safety
Black-box Warning
Black-box warning for: Duavee, Menest, Premarin, Premphase, Premphase prempro, Prempro
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
61,413 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use